<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187691</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70006</org_study_id>
    <nct_id>NCT03187691</nct_id>
  </id_info>
  <brief_title>Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia</brief_title>
  <official_title>An Open Label Phase II Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous (AML) and Lymphoblastic Leukaemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clinical Trials Centre Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Non-randomized, prospective , multicenter, open uncontrolled study in patients with acute
      myelogenous (AML) or lymphoblastic leukaemia (ALL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label phase II clinical study to evaluate the safety and pharmacokinetics of
      oral encochleated Amphotericin B (CAMB/MAT2203) for prevention of invasive fungal infections
      in approximately 30 patients undergoing induction therapy for AML/ALL.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-randomized, open uncontrolled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>35 days</time_frame>
    <description>Safety assessments include laboratory tests, vital signs, physical exam and ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetic (PK) analysis</measure>
    <time_frame>35 days</time_frame>
    <description>PK parameter for Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetic (PK) analysis</measure>
    <time_frame>35 days</time_frame>
    <description>PK parameter for Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetic (PK) analysis</measure>
    <time_frame>35 days</time_frame>
    <description>PK parameter for Area under the plasma concentration time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy analysis for time to clinical symptoms of fungal infection</measure>
    <time_frame>35 days</time_frame>
    <description>Clinical symptoms of fungal infections include evaluation of respiratory symptoms, sinuses, skin.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg CAMB (MAT2203) Oral Amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg CAMB (MAT2203) Oral Amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAMB 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg CAMB (MAT2203) Oral Amphotericin B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Encochleated Amphotericin B (CAMB)</intervention_name>
    <description>Lipid-crystal nano-particle formulation amphotericin B</description>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <arm_group_label>CAMB 800mg</arm_group_label>
    <other_name>MAT2203</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed AML/ALL receiving chemotherapy inducing neutropenia &lt; 500 cells/mm3

          -  Able to have all screening tests done to allow for study drug administration no later
             than 5 days after start of chemotherapy

          -  Sign informed consent

          -  ≥ 18 years of age

        Exclusion Criteria:

          -  Known hypersensitivity to amphotericin B, specifically anaphylactic reaction

          -  Fungal induced fever (≥ 38°C)

          -  Proven, possible or probably invasive fungal infection in previous 12 months

          -  Serum galactomannan index (GMI)≥ 0.5 at screening

          -  Pulmonary infiltrates at screening

          -  Current treatment with amphotericin B

          -  Sever comorbidity other than underlying haematological disease

          -  Prolongation of corrected QT interval

          -  History of convulsion

          -  Pregnant or breastfeeding

          -  Females of childbearing potential who do not practice sexual abstinence or who do not
             agree to use appropriate contraceptive methods

          -  Presence of hepatic disease

          -  Total bilirubin &gt; 3 x upper limit of normal

          -  Age-adjusted creatinine clearance &lt; 30 mL/minute

          -  Participating in any other clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Cornely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roelof Rongen</last_name>
    <phone>908-627-3373</phone>
    <email>rrongen@matinasbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Johnson</last_name>
    <phone>9082953235</phone>
    <email>jjohnson@matinasbiopharma.com</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

